Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:

NCT ID: NCT03989349 Completed - Clinical trials for Moderate-to-Severe Atopic Dermatitis

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Start date: June 30, 2019
Phase: Phase 3
Study type: Interventional

The main purpose of the study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

NCT ID: NCT03989206 Active, not recruiting - Clinical trials for Moderate-to-Severe Atopic Dermatitis

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Start date: December 30, 2019
Phase: Phase 3
Study type: Interventional

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

NCT ID: NCT03985943 Completed - Clinical trials for Moderate-to-Severe Atopic Dermatitis

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Start date: June 30, 2019
Phase: Phase 3
Study type: Interventional

The main purpose of the study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

NCT ID: NCT03981926 Active, not recruiting - Atopic Dermatitis Clinical Trials

Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis

TCH in AD
Start date: August 27, 2019
Phase: N/A
Study type: Interventional

This is a pragmatic, randomized, controlled, equivalency trial. This 12-month trial will evaluate the impact of an online, team-based connected health (TCH) model for management of atopic dermatitis (AD) as compared to in-person care. 300 patients will be randomly assigned to the online TCH model or the in-person control arm. This pragmatic, randomized trial will compare AD disease severity (Aim 1), quality-of-life and access-to-care measures (Aim 2), and costs (Aim 3) between the two models.

NCT ID: NCT03976622 Not yet recruiting - Psoriasis Clinical Trials

Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

INFLAMMAVit
Start date: June 3, 2019
Phase:
Study type: Observational

It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders

NCT ID: NCT03962387 Active, not recruiting - Atopic Dermatitis Clinical Trials

Evalution the Safety and Efficacy in Atopic Dermatitis Patients

Start date: April 5, 2019
Phase:
Study type: Observational

A multi-center, open, long-term follow-up study to evaluate the efficacy and safety of FURESTEM-AD inj. in patients with moderate to severe chronic atopic dermatitis: 5-year results from the K0102 extension study

NCT ID: NCT03961529 Completed - Atopic Dermatitis Clinical Trials

Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis

Start date: May 14, 2019
Phase: Phase 3
Study type: Interventional

To demonstrate the safety of 1% OPA-15406 ointment in adult patients with AD and of 0.3% and 1% OPA-15406 ointments in pediatric patients with AD administered twice daily for 52 weeks.

NCT ID: NCT03954158 Completed - Atopic Dermatitis Clinical Trials

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Start date: June 15, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2b, multi-center, randomized, double-blind, vehicle-controlled, intraparticipant study to evaluate efficacy and safety of two regimens of crisaborole ointment 2% in Japanese pediatric and adult participants (cohort 1: 12 years and older, cohort 2: 2 to under 12 years old) with mild to moderate Atopic Dermatitis (AD).

NCT ID: NCT03952559 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

BREEZE-AD-PEDS
Start date: May 24, 2019
Phase: Phase 3
Study type: Interventional

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

NCT ID: NCT03948334 Terminated - Atopic Dermatitis Clinical Trials

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

ZESTExt
Start date: April 4, 2019
Phase: Phase 2
Study type: Interventional

This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the core study (CZPL389A2203/ NCT03517566) which is disclosed separately. It aimed to assess the short-term and long-term safety of (blinded) 30 mg o.d and 50 mg o.d ZPL389 with concomitant or intermittent use of topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCI).